Skip to main content
SpringerLink
Log in

The Biomarkers Consortium

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

The Biomarkers Consortium is a public–private biomedical research partnership that seeks to develop and qualify biomarkers across a broad range of diseases in order to accelerate the development of new medicines and improve patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Talbot, G. H. et al. on behalf of the CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55, 1114–1121 (2012).

    Article  Google Scholar 

  2. File, T. M. Jr et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin. Infect. Dis. 51, 1395–1405 (2010).

    Article  CAS  Google Scholar 

  3. Boucher, H. W. et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 370, 2169–2179 (2014).

    Article  Google Scholar 

  4. Esserman, L. J. & Woodcock, J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 306, 2608–2609 (2011).

    Article  CAS  Google Scholar 

  5. Prowell, T. M. & Pazdur, R. Pathological complete response and accelerated drug approval in early breast cancer. N. Engl. J. Med. 366, 2438–2441 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Foundation for the National Institutes of Health, Bethesda, 20814, Maryland, USA

    David Wholley

Authors
  1. David Wholley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Wholley.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Biomarkers Consortium Membership (PDF 134 kb)

Supplementary information S2 (table)

Summary of Biomarkers Consortium Projects (PDF 111 kb)

Related links

Related links

FURTHER INFORMATION

Biomarkers Consortium

Foundation for the National Institutes of Health

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry community-acquired bacterial pneumonia: developing drugs for treatment (HFA-305)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wholley, D. The Biomarkers Consortium. Nat Rev Drug Discov 13, 791–792 (2014). https://doi.org/10.1038/nrd4439

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4439

  • Springer Nature Limited

This article is cited by

Search

Navigation